ライフサイエンスコーパス: at delivery

1 rmine whether levels differed by infant size at delivery.

2 ir showed improvement in HBV DNA suppression at delivery.

3 ted HAART during pregnancy had detectable VL at delivery.

4 should be considered when assessing VTE risk at delivery.

5 rence were more likely to have detectable VL at delivery.

6 doses of IPTp but rebounded to 34% (by PCR) at delivery.

7 . falciparum infection and hemoglobin levels at delivery.

8 factors; and detectable VL (>400 copies/mL) at delivery.

9 , and BPD at weeks 20-34, and with BW and HC at delivery.

10 d matching maternal blood samples were taken at delivery.

11 others who had Plasmodium falciparum malaria at delivery.

12 clusion criteria and 13.1% had detectable VL at delivery.

13 regnancy, were associated with detectable VL at delivery.

14 (PTH) in maternal circulation and cord blood at delivery.

15 hy eating, and exercise and was discontinued at delivery.

16 status of the placenta can only be assessed at delivery.

17 rd level was 66% of the maternal serum level at delivery.

18 l blood and placental samples were retrieved at delivery.

19 specimens from 293 pregnant Mozambican women at delivery.

20 ood discriminatory power in patients with PE at delivery.

21 de pair implanted 1 mm away from the site of AT delivery.

22 -negative, and 15,994 had unknown HIV status at delivery.

23 k of preterm delivery and uterine dehiscence at delivery.

24 n newborns of women with and without malaria at delivery.

25 Standardized evaluations were performed at delivery.

26 were detected over the course of therapy or at delivery.

27 d of women with or without placental malaria at delivery.

28 s in clinical parameters at midpregnancy and at delivery.

29 estation; umbilical cord blood was collected at delivery.

30 BL levels were measured during pregnancy and at delivery.

31 stology) and maternal peripheral parasitemia at delivery.

32 r contamination with infected maternal blood at delivery.

33 tal status, and maternal county of residence at delivery.

34 borns of multigravid and/or uninfected women at delivery.

35 ternal cadmium, mercury, or manganese levels at delivery.

36 egnancy body mass index, and gestational age at delivery.

37 tus, age, fetal growth, or week of gestation at delivery.

38 ive hallucinations, and intermittent amnesia at delivery.

39 prenatal care, or had longer hospital stays at delivery.

40 , in part, by the postnatal rise in cortisol at delivery.

41 g an underreporting of psychiatric disorders at delivery.

42 or the 107 women who had undetectable levels at delivery.

43 ed in serial maternal samples and cord blood at delivery.

44 livery; and the presence of chorioamnionitis at delivery.

45 7 (49.4%) were to women enrolled in Medicaid at delivery.

46 (2%) of 33,376 babies, were judged abnormal at delivery.

47 neonatal mortality rates by gestational age at delivery.

48 virus populations taken during pregnancy and at delivery.

49 nary arteries, and increased the fall in PVR at delivery.

50 f maternal blood obtained at study entry and at delivery.

51 d and matched based on age and calendar year at delivery.

52 was detected in 91 of 819 placentas (11.1%) at delivery.

53 r GBS colonization at antenatal screening or at delivery.

54 outcome was malaria infection in the mother at delivery.

55 ted women, 95% of whom (790/828) were on ART at delivery.

56 ations) were identified during pregnancy and at delivery.

57 very, with matched maternal and cord samples at delivery.

58 the early pregnancy samples and those taken at delivery.

59 ength measured during mid-pregnancy, but not at delivery.

60 normotensive (n=42) pregnant women recruited at delivery.

61 respectively but only 49% (95% CI, 31%, 66%) at delivery.

62 rritin or hepcidin as iron-status indicators at delivery.

63 cantly negatively associated with hemoglobin at delivery.

64 ated with higher fetal loss and more malaria at delivery.

65 t trimester, during the third trimester, and at delivery.

66 ups were a mean (SD) age of 28.9 (5.1) years at delivery.

67 e is rectovaginal colonisation of the mother at delivery.

68 mens, and cord blood specimens were obtained at delivery.

69 ropoietin is a sensitive predictor of anemia at delivery.

70 CI: -5.91, 2.44) than a positive urine test at delivery (-182 g (95% CI: -295, -69.8) and -6.11 mm (

71 creased the odds of stillbirth when detected at delivery (2.81 [0.77-10.22]; three estimates), but no

72 oral cavity and stool samples were analyzed at delivery, 21 +/- 7 days (D21), and 60 +/- 7 days (D60

73 ot differ between groups during gestation or at delivery: 24 women in the iodine group and 28 in the

74 cies were identified (mean [SD] maternal age at delivery, 25.2 [6.0] years in Medicaid and 31.6 [4.6]

75 in maternal and cord blood samples obtained at delivery (251 maternal-newborn pairs), and birth weig

76 -based cohort of 1.3 million women, mean age at delivery 28 years, with nearly 1.9 million completed

77 ernal samples in early pregnancy (12-16 wk), at delivery (28-42 wk), and in cord blood.

78 of postpartum women (median gestational age at delivery 30 weeks).

79 At delivery, 30 of 126 women (24%) experienced massive b

80 standard care (mean [+/-SD] gestational age at delivery, 30.8+/-2.0 weeks vs. 37.0+/-1.5 weeks; P<0.

81 Among QGIT-positive women antepartum or at delivery, 34 (12%) reverted to QGIT-negative after IP

82 s (15% vs 14%, 1.45, 0.73-2.90) or gestation at delivery (36.6 weeks vs 36.8 weeks; mean difference -

83 in plasma during early pregnancy (12-16 wk), at delivery (37-42 wk), and in cord blood samples from 2

84 ysis of serotype-specific antibody responses at delivery (+72 h) for use in subsequent studies.

85 differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-

86 r paper and blood slides were collected, and at delivery, a placental biopsy was collected.

87 th-weight percentile and the gestational age at delivery; after adjustment for these factors, the odd

88 Cord plasma at delivery also had higher concentrations of d3-RRR-alp

89 ll women with malaria are still parasitaemic at delivery, an estimated 20% of the 1 059 700 stillbirt

90 blood, cervical secretions, and breast milk at delivery and 1 month after delivery.

91 4 weeks after Tdap immunization or placebo, at delivery and 2 months' postpartum, and in infants at

92 s after dose 2, and, in mothers and infants, at delivery and 3 and 6 months postdelivery.

93 s by delivery companies to verify their ages at delivery and 95% of delivered orders simply left at t

94 ations between different measures of malaria at delivery and adverse birth outcomes are limited.

95 , periodontal treatment, and gestational age at delivery and birth weight.

96 s (P <.05) when adjusted for gestational age at delivery and birth weight.

97 Infant gestational age at delivery and changes in maternal bra cup size between

98 om two studies in which maternal PFAS levels at delivery and children's PFAS levels were available.

99 peripheral, placental, cord blood specimens) at delivery and composite birth outcome (small for gesta

100 vudine improved maternal HBV DNA suppression at delivery and during 4-8 weeks' postpartum follow-up.

101 osed to malarial antigens either in utero or at delivery and have the potential to produce antimalari

102 ogical endpoints such as placental infection at delivery and health outcomes including birthweight, w

103 orporated early life (including mother's age at delivery and HIV status) and current life factors (in

104 Thyroid hormone levels were also assessed at delivery and in cord blood (n = 260).

105 of specific antibody in mother-infant pairs at delivery and in infants at 16 weeks, determined by en

106 mothers at 15 and 28 weeks of pregnancy and at delivery and in their infants in umbilical cord blood

107 ts were measured in blood samples from women at delivery and in umbilical cords, and in infants for e

108 disturbance was unrelated to gestational age at delivery and persisted for up to 1 y.

109 sures in women before and after vaccination, at delivery and post partum.

110 ad longitudinal testing, with repeat testing at delivery and postpartum and additional cytokines meas

111 m and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

112 m and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

113 ate associations between measures of malaria at delivery and risks of low birth weight (LBW), small f

114 n were recruited into a retrospective cohort at delivery and tested for syphilis.

115 icance included a higher maternal virus load at delivery and the presence of cocaine in the urine.

116 PT was analyzed according to maternal VL at delivery and timing of ART initiation.

117 aternal blood taken earlier in pregnancy and at delivery and to relate formate concentrations to pote

118 Secondary endpoints were VL at delivery and tolerance.

119 versus pregnant women (during pregnancy, not at delivery) and by gravidity, and we used meta-regressi

120 .6% of women studied (n = 37/83) were anemic at delivery, and 18% of women (n = 11/61) had IDA.

121 regnancy had a 2-fold greater risk of anemia at delivery, and 25% (n = 5) developed iron deficiency a

122 fore vaccination, 1 month after vaccination, at delivery, and at postpartum week 24 in mothers and wi

123 placental malaria, maternal hemoglobin level at delivery, and birth weight.

124 ore vaccination (day 1), day 15, day 31, and at delivery, and in infants at birth and day 42 of life.

125 antly lower risk of placenta malaria, anemia at delivery, and low birth weight.

126 At delivery, antibody responses did not differ between s

127 birth during the same year, gestational age at delivery, Apgar score at 5 minutes, maternal and pate

128 pregnancy ( approximately 24 wk; n = 73) and at delivery ( approximately 35 wk; n = 61) were used to

129 Antiparasite IgGs in women at delivery are affected by HIV infection, as well as by

130 others had a malaria-infected placenta (MIP) at delivery are at increased risk of a first malaria inf

131 atally, ECMO requirement and gestational age at delivery are useful in further improving the estimate

132 ng phenotypic changes, which can be detected at delivery, are associated with birth weight and gestat

133 a in pregnancy often use measures of malaria at delivery as their primary outcome.

134 ally correlated with younger gestational age at delivery (B = -0.18, p = 0.05).

135 ts born to mothers who were HCV RNA positive at delivery became infected, compared with 0 of 54 infan

136 r cohort, with the average age of the mother at delivery being 29.8 years (IQR 26-34).

137 n aged over 10 years, with a gestational age at delivery between 22 and 44 weeks, and excluded deaths

138 edical record data included gestational week at delivery, birth weight, resuscitation, neonatal inten

139 nal and cord plasma from 259 Caucasian women at delivery (BMI 18-55 kg/m(2)).

140 or infants born to mothers with low ferritin at delivery, breastfed infants not receiving iron-fortif

141 ignificantly associated with gestational age at delivery but not with fetal sex.

142 as been associated with reduced birth weight at delivery but results are not consistent.

143 birthweight is low for their gestational age at delivery, but past analyses have been hampered by sma

144 with a lower prevalence of malaria than SST at delivery, but the prevalence of malaria in this group

145 n significantly decreased the risk of anemia at delivery by 40% (RR, 0.60; 95% CI, 0.51-0.71) but not

146 reduced the risk of maternal iron deficiency at delivery by 52% (RR, 0.48; 95% CI, 0.32-0.70) and the

147 ctions were assessed in 272 Mozambican women at delivery by microscopy, placental histology, quantita

148 Birth outcomes were completed at delivery by midwives who also collected cord blood sa

149 this study was to test whether maternal age at delivery, child's birth order, cesarean section, comp

150 Analysis of plasma from the at-delivery cohort confirmed the ability of this biomark

151 use of PE (n = 13) or other causes (n = 21) (at-delivery cohort).

152 3), 10.5% among women with malaria infection at delivery compared to 7.9% among uninfected women (aRR

153 p, and within the IPTp-MQ group it was lower at delivery compared with recruitment.

154 ion had improved hematologic and iron status at delivery compared with the placebo group.

155 dministration, preeclampsia, gestational age at delivery, days in intensive care unit, sex, age, and

156 y and mortality increases as gestational age at delivery decreases.

157 The primary outcome was malaria infection at delivery, defined as a composite of peripheral or pla

158 ensity was calculated as actual birth weight at delivery divided by fetal body volume at MR imaging i

159 At delivery, ECGs were recorded and analyzed for conduct

160 her GMCs than did those in the placebo group at delivery (eg, GMCs against serotype Ia were 11 mug/mL

161 GMCs of maternal antibodies at delivery (ELISA units/mL) were 2.4 for PT, 6.9 for FH

162 is necessary to screen for domestic violence at delivery, especially for women who may not have obtai

163 ts may be more vulnerable to HIV acquisition at delivery, especially if membrane rupture is prolonged

164 RI)] and placental active transport capacity at delivery [fetal to maternal measles antibody (MMA) ra

165 Six of these samples were male at delivery, five had inconclusive results for SRY analy

166 Data were available at delivery for 2356 women, with 2345 livebirths; 2115 (

167 ternal and cord blood samples were collected at delivery for DNA extraction.

168 nt women in their second/third trimester and at delivery for LTBI using the tuberculin skin test (TST

169 =55) Mozambican pregnant women were assessed at delivery for maternal and cord P. falciparum infectio

170 HIV-viral load was measured at delivery for mothers and at 6 weeks of age for infant

171 ed maternal and umbilical cord blood samples at delivery from 622 mother-infant pairs residing near a

172 Plasma samples obtained at delivery from 885 pregnant Ghanaian women were tested

173 Here, we assayed plasma collected at delivery from Malian and Tanzanian women of different

174 Birth outcomes were abstracted at delivery from medical records.

175 ples were taken from 201 pregnant women and, at delivery, from the umbilical cord veins of their heal

176 ding birthweight, birth length, parental age at delivery, gestational age, intrauterine exposure to d

177 Maternal plasma and lipoproteins obtained at delivery had higher concentrations of d3-RRR-alpha-to

178 The use of a polyethylene wrap applied at delivery has been shown to reduce the occurrence of h

179 risk for hydrops and respiratory compromise at delivery have not been well defined.

180 At delivery, high IL-10 levels in maternal blood were as

181 At delivery, higher AGP levels were strongly associated

182 At delivery, HIV-infected mothers and their infants were

183 an antibody concentration in blood collected at delivery); however, at birth, maternally derived sero

184 blood-derived maternal virus genotypes found at delivery if infants were found to be infected only so

185 d at midgestation ( approximately 26 wk) and at delivery in 171 adolescents (</= 18 y).

186 and plasma was measured during gestation and at delivery in mothers who did and did not transmit HIV

187 d maternal or placental plasmodium infection at delivery in multigravidae (third pregnancy or higher)

188 ticoids are lower in maternal and cord blood at delivery in obese pregnancies.

189 Plasmodium falciparum malaria detected at delivery in peripheral samples increased the odds of

190 y (time-varying treatment) on odds of anemia at delivery in the presence of time-dependent confoundin

191 ations of pertussis antibodies were measured at delivery in women who received Tdap during pregnancy

192 At delivery, in both analyses, we observed negative asso

193 ve been described in placenta and cord blood at delivery, in fetal lung, and in buccal epithelium and

194 vast majority of women with low viral loads at delivery, in the absence of obstetrical risk factors,

195 roughout the course of pregnancy, as well as at delivery, in women with asymptomatic infections and t

196 mple size, along with the use of infant size at delivery instead of longitudinal ultrasound measures

197 tcomes were birth weight and gestational age at delivery, intrauterine growth, and maternal and infan

198 Among 6099 women at delivery, IPTp-SP was associated with a 22% reduction

199 ine whether older or very young maternal age at delivery is associated with mental retardation in chi

200 Whether this is maintained at delivery is unknown but is clinically relevant as mat

201 At delivery, malaria prevalence was 20.2% (128 of 633) i

202 Conditions at delivery may overcome any potential negative effects

203 sis had an earlier estimated gestational age at delivery (mean, 38.6 weeks; 95% CI, 38.2-38.9) than t

204 We collected maternal and cord blood at delivery, measured manganese using inductively couple

205 present in 67% of mothers and 65% of infants at delivery (median 66 days after dose 2), 60% of mother

206 Despite low maternal folate status at delivery (median: 9.0 nmol/L), with 35% of women in t

207 At delivery, median durations of ART were 13 weeks (IQR,

208 The mothers' own pups were removed at delivery; mothers were nonmaternal at the time of tes

209 ly, and their newborn infants, were enrolled at delivery (n = 35 mother-infant pairs).

210 n was noted in paired maternal-blood samples at delivery (n=16) or amplicon levels in cord-blood samp

211 = 0.0%, N = 4,092), peripheral parasitaemia at delivery (odds ratio (OR) 2.28, 95% CI 1.46; 3.55, p-

212 confidence interval, 1.2 to 4.7; P=0.02) and at delivery (odds ratio, 3.4; 95 percent confidence inte

213 g people were analyzed, with a mean (SD) age at delivery of 28 (6) years.

214 dence interval) (in mug/L) in maternal serum at delivery of PFOS [8.50 (7.01-9.58)] and PFOA [3.43 (3

215 relate with CD4 cell count or HIV-1 RNA load at delivery or with type of antepartum antiretroviral th

216 OR, 3.38 [95% CI, 1.65-6.93]) and viral load at delivery (OR, 2.35 [95% CI, 1.62-3.40]) independently

217 er liter or more, intubation for ventilation at delivery, or neonatal encephalopathy.

218 maternal hemoglobin at both midgestation and at delivery (P < 0.01 for both).

219 a and transport length, respectively) and GA at delivery (P = .005 and P = .04).

220 nation (ECMO) (P < .001) and gestational age at delivery (P = .009).

221 as inversely correlated with gestational age at delivery (P = 0.0039).

222 clusters demonstrated lower gestational age at delivery (p = 0.049), increased protein excretion (p

223 03 and 5116] HIV-1 RNA copies per milliliter at delivery; P < .001) and none transmitted.

224 , ancestry, neonatal gender, gestational age at delivery, parity, maternal age at oral glucose tolera

225 d with nevirapine resistance were detectable at delivery, prior to receipt of study drug, in 5 (2.3%)

226 At delivery, proportions with VL <200 copies/mL were sim

227 At delivery, QGIT identified 205 and TST 113 women with

228 epregnancy BMI, marital status and insurance at delivery, race, smoking during target pregnancy, and

229 s calculated as the enrichment in cord blood at delivery relative to maternal serum enrichment 2 h po

230 (2721, 2867 nmol/L ) in early pregnancy and at delivery, respectively.

231 od samples were obtained at midgestation and at delivery, respectively.

232 independent risk factors, in addition to GA at delivery, SGA, multiple births, and male sex.

233 At delivery, significantly lower HBV DNA levels were not

234 own risk factors (i.e., gestational age [GA] at delivery, small for gestational age [SGA], multiple b

235 is multifactorial, high maternal virus load at delivery strongly predicts transmission.

236 51 vs 0.16 Mn:Ca, p < 0.001), maternal blood at delivery than 26 weeks gestation (GM = 20.7 vs. 14.6

237 4.3-fold higher median plasma HIV RNA level at delivery than did nontransmitters (P<.001).

238 vels higher than 50000 copies per milliliter at delivery than nontransmitting mothers (15 [75.0%] of

239 kely to have aNAB to their own HIV-1 strains at delivery than nontransmitting mothers (n = 17, 14.3%

240 ificantly lower HIV-1 quasispecies diversity at delivery than untreated nontransmittting mothers (n =

241 38 days the anaemic fetuses were transfused; at delivery the haematocrit was 29.3 +/- 6.8 % compared

242 um) of increase in the maternal serum level (at delivery), the associations being strongest for 4 yea

243 At delivery, the infant also had vitamin A deficiency.

244 At delivery, the LNS (n = 1184) and control (n = 1185) g

245 parity, and the offspring's gestational age at delivery, the odds ratio for an adult whose mother ha

246 In this longitudinal study of malaria at delivery, the receipt of SP as IPTp did not potentiat

247 At delivery, the TDF group had lower maternal HBV DNA le

248 weeks gestation and placental and cord blood at delivery to assess inflammatory status.

249 We screened 128,049 pregnant women at delivery to identify three groups of infants: those e

250 , and Nutrition study were randomly assigned at delivery to receive: LNS, ARV, LNS and ARV, or a cont

251 has been widely prescribed to pregnant women at delivery, to reduce mother-to-child transmission of h

252 ions of DEHP metabolites and gestational age at delivery using linear regression models and associati

253 an plasma viral load of 65,516 RNA copies/mL at delivery versus 5139 in nontransmitting women.

254 heir infection to their children in utero or at delivery (vertical transmission).

255 scertained via verbal autopsy and HIV status at delivery via annual HIV surveys.

256 ere female, and the median (SD) maternal age at delivery was 25 (6) years.

257 Mean (SD) age at delivery was 29.5 (5.3) years.

258 The weight at delivery was 3.5 +/- 0.36 kg in the anaemic fetuses v

259 The median gestational age at delivery was 30.7 weeks (IQR 29.1-32.1) and mean birt

260 Mean birthweight at delivery was 3463 g (SD 660) in the placebo group and

261 Mean gestational age at delivery was 37 weeks, with 100% survival.

262 The mean gestational age at delivery was 38 weeks.

263 e at enrollment and race, the odds of anemia at delivery was 8 times greater in adolescents with deli

264 Malaria parasitemia at delivery was associated with an adjusted decrease in

265 Malaria at delivery was detected using peripheral and placental

266 The estimated gestational age at delivery was earlier for study patients (33.2 vs 37.0

267 Venous cord blood collected at delivery was evaluated for transplacental transfer of

268 The prevalence of malaria at delivery was higher in the ISTp-DP arm (48.7% versus

269 HIV viral load at delivery was higher in the MQ group compared to the c

270 Prevalence of malaria infection at delivery was lower in the intermittent preventive tre

271 A detectable HIV-viral load at delivery was more common among pregnant women with tu

272 A positive hair test at delivery was not more strongly associated with birth

273 Gestational age at delivery was significantly greater in those who recei

274 istance, adjusted for plasma viral RNA level at delivery, was not strongly associated with an increas

275 Of 17,046 women enrolled at delivery, we assessed 11,867 women (69.6%) at 11.5 y

276 At delivery, we collected a placental-tissue sample and

277 At delivery, we collected samples from placenta (fetal s

278 smoking, BMI, child sex, and gestational age at delivery, we identified 188 CpG sites where placental

279 SRY real time PCR results and fetal sex at delivery were 100% accurate.

280 ts, for which the mean (SD) gestational ages at delivery were 38.4 (2.1) weeks, 35.8 (2.8) weeks, and

281 and umbilical cord plasma samples collected at delivery were analyzed for medication concentrations.

282 Outcomes at delivery were as follows: normal placenta (n = 11), h

283 There was no evidence that MBL levels at delivery were associated with malaria-related poor pr

284 Pregnancies with OP positions at delivery were compared with those with occiput anteri

285 the 7 study clinics and were >=18 years old at delivery were eligible for endpoint assessment.

286 Matched maternal and neonatal sera obtained at delivery were functionally equivalent in an in vitro

287 Plasma HIV RNA levels at delivery were higher among transmitters (mean, 68,921

288 complete data on smoking and gestational age at delivery were included.

289 ons between average DAPs and growth measures at delivery were positive but not significant for head c

290 primary results for participants and infants at delivery were published in 2012; we present results f

291 rinated biphenyls in maternal serum and milk at delivery were slightly higher than in the general pop

292 Mother-neonate paired serum samples at delivery were tested for IgG to antigens from P. falc

293 Maternal blood DHA concentrations at delivery were unrelated to outcomes, although materna

294 (1) When anal sphincter injury occurs at delivery, what is the most effective method of repair

295 aternal tHcy was lower during pregnancy than at delivery, whereas folate and vitamin B-12 status decl

296 Inflammation was present at delivery, which limited the utility of ferritin or he

297 8, 19.4) of the variation in gestational age at delivery, while maternal genetic factors accounted fo

298 ons, including those who present in labor or at delivery whose HIV status is unknown.

299 ted retesting during late antenatal care and at delivery with either individual tests (scenario two)

300 relatively homogeneous across all body sites at delivery, with the notable exception of the neonatal